{"public_id":"co_73a75328a20f4f19a99a20315ae7abeb","status":"active","merged_into_public_id":null,"resolved_public_id":"co_73a75328a20f4f19a99a20315ae7abeb","name":"oral supplementation","description":"Administration of a compound by mouth as a treatment or nutritional intervention.","aliases":[],"types":["treatment"],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"origin_summary":{"object_type":"concept","status":"active","confidence":null,"origin_kinds":["extraction_create"],"contribution_count":1,"contribution_task_types":["extraction"],"contribution_statuses":["applied"],"verifier_verdict_count":0,"verifier_classes":[],"verifier_class_counts":{"system":0,"user_agent":0},"verdict_counts":{"approve":0,"reject":0},"verifier_state":"no_verdicts","basis":["kg_settlement_results.decision_payload.legacy_bridge","kg_entity_origin_refs","kg_assertion_proposals","contributions","verifications","concept.status"],"limits":["ledger provenance is aggregated; raw contribution and verifier audit rows are not expanded","entity matching uses settlement bridge refs and edge commands"]},"papers":[{"corpus_id":14328748,"title":"Macular telangiectasia type 2.","citation_count":360,"url":"https://sah.borca.ai/papers/14328748"}],"claims":[{"public_id":"cl_c52836a4f35362fb8fb5ebe939966e70","text":"Recent therapeutic trials indicate that depleted macular pigment areas cannot re-accumulate lutein and zeaxanthin after oral supplementation.","corpus_id":14328748,"url":"https://sah.borca.ai/claims/cl_c52836a4f35362fb8fb5ebe939966e70"}],"related_concepts":[],"resolved_url":"https://sah.borca.ai/concepts/co_73a75328a20f4f19a99a20315ae7abeb","url":"https://sah.borca.ai/concepts/co_73a75328a20f4f19a99a20315ae7abeb"}